Prognostic value of nucleotide excision repair and translesion DNA synthesis proteins in muscle-infiltrating bladder carcinoma
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.High expression of XPG and POLI proteins, involved in DNA repair pathways like nucleotide excision repair (NER) and translesion DNA synthesis (TLS), correlates with poorer survival in muscle-infiltrating bladder carcinoma (MIBC) patients treated with cisplatin.
Area Of Science
- Oncology
- Molecular Biology
- Genetics
Background
- Cisplatin (CDDP) is a key chemotherapy for muscle-infiltrating bladder carcinoma (MIBC).
- Chemoresistance in MIBC may stem from enhanced DNA damage repair.
- Prognostic value of DNA repair proteins in MIBC requires further investigation.
Purpose Of The Study
- To investigate the prognostic significance of nucleotide excision repair (NER) and translesion DNA synthesis (TLS) proteins in MIBC patients.
- To identify potential biomarkers for predicting treatment response and survival outcomes.
Main Methods
- Retrospective analysis of 86 MIBC patients' tumor samples.
- Immunohistochemical staining for XPA, XPF, XPG, ERCC1, POLI, POLH, and REV3L proteins.
- Analysis of NER and TLS pathway expression in relation to overall survival (OS) and multivariate analyses (MVA).
Main Results
- Tumor expression of XPG and POLI was significantly associated with worse overall survival (OS) in the total MIBC cohort.
- Increased expression of both NER and TLS pathways correlated with inferior OS.
- High POLI expression independently predicted poor OS in metastatic urothelial carcinoma (mUC) patients receiving first-line gemcitabine and CDDP.
Conclusions
- Tumor expression of XPG and POLI, and the overall NER and TLS pathways, are significant prognostic biomarkers for inferior OS in MIBC.
- These proteins and pathways represent potential therapeutic targets for improving MIBC treatment outcomes.
- Further prospective trials are necessary to validate these findings and their clinical utility.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
